Cardiometabolic Disease and COVID-19: Risk, Treatment and Trials

Published: 13 July 2020

  • Views:

    Views Icon 304

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

In this series, Mikhail Kosiborod and Hertzel Gerstein discuss the effects of Covid-19 and metabolic disease, early treatment with metabolic therapies and the Phase III DARE-19 Trial looking at dapagliflozin in Covid-19 patients.

Recorded remotely from Hamilton and Kansas City, 2020.

This discussion was supported by an unrestricted educational grant from Novo Nordisk.

More from this programme

Part 1

The Effect of COVID and Metabolic Disease and Early Treatment

Dr Mikhail N Kosiborod (Saint Luke's America Heart Institute, Kansas City, US) joins Prof Hertzel Gerstein (McMaster University, Hamilton, ON, CA) to discuss the current landscape of cardiometabolic therapies for COVID-19. Dr Kosiborod talks about the cardiometabolic risk factors for death in people who are hospitalised with COVID-19.
1 session
The Effect of COVID and Metabolic Disease and Early Treatment Watch now

Part 2

Metabolic Therapy Treatments

Prof Gerstein (McMaster University, Hamilton, ON, CA) and Dr Kosiborod (Saint Luke's America Heart Institute, Kansas City, US) discuss whether organ protection can complement other treatments for COVID-19. Dr Kosiborod discusses DARE-19, an international study evaluating the effect of dapagliflozin versus placebo in addition to background therapy, in reducing disease progression, complications and all-cause mortality.
1 session
Metabolic Therapy Treatments Watch now

Part 3

Phase III DARE-19 Trial

Dr Mikhail N Kosiborod (Saint Luke's America Heart Institute, Kansas City, US) talks about the DARE-19 trial, an international study evaluating the effect of dapagliflozin versus placebo in addition to background therapy, in reducing disease progression, complications, and all-cause mortality.
1 session
Phase III DARE-19 Trial Watch now

Faculty Biographies

Mikhail Kosiborod

Mikhail Kosiborod

Cardiologist

Dr Mikhail Kosiborod is a cardiologist, the Vice President of Research at Saint Luke's Health System, and Professor of Medicine at the University of Missouri-Kansas City, US.

He is also Director of Cardiometabolic Research and Co-Director of the Saint Luke’s Michael & Marlys Haverty Cardiometabolic Center of Excellence at Saint Luke's Mid America Heart Institute. Dr Kosiborod is an internationally-recognised expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes.

Dr Kosiborod is involved in the leadership of numerous clinical trials and multi-center registries, and is currently the principal investigator of several investigator-initiated, multi-center trials in diabetes and cardiovascular disease.

View full profile
Hertzel C Gerstein

Hertzel C Gerstein

Endocrinologist

Dr Hertzel C Gerstein is an Endocrinologist and Professor at McMaster University and Hamilton Health Sciences, where he holds the Population Health Institute Chair in Diabetes Research. 

View full profile